Taipei Taiwan – November 24th, 2021 – iXensor Co., Ltd. (6734.TWO)
iXensor, the pioneer of mobile health, wins the Taiwan Excellence Gold Award for its computer vision-aided PixoTest® COVID-19 Antigen Test, together with its enterprise PixoHealth Pass Solution. The integrated point-of-care diagnostics and health management SaaS product offers an innovative end-to-end COVID-19 screening solution for outbreak prevention. PixoTest® COVID-19 Antigen Test is the third digital health product of iXensor honored with the Taiwan Excellence Award and the first to receive the Gold Award.
In response to solving common pain points of rapid test, iXensor deployed the patented digital diagnostic PixoTech® technology, integrating the algorithm of image analysis, biochemical tests, and health data management, to launch the digital PixoTest® COVID-19 Antigen Test in mid-2021. By utilizing the PixoTest® POCT Analyzer, PixoTest® standardizes test reading, reduces human errors of inaccurate interpretation, and shortens the waiting time for identifying COVID-19 infected people from several hours to only a few minutes.
Established by Taiwan’s Ministry of Economic Affairs in 1993, the Taiwan Excellence Gold Award recognizes innovation and excellence across various industries. It is regarded as the highest honor in Taiwan for industrial design, research and development, quality management, and marketing. iXensor’s PixoTest® COVID-19 Antigen Test was selected to receive the Gold Award out 1179 applications from 210 companies.
The CEO of iXensor, Dr. Carson Chen, commented at the ceremony: “In the post-pandemic era, the world needs a sustainable solution to co-live with recurrences of COVID-19. PixoTest® not only embodies the core competencies of Taiwan’s MedTech and ICT industries but offers corporations, manufacturers, schools, and healthcare authorities a way to better manage the safety while reopening economies.”
About iXensor
iXensor, the pioneer of mobile health, turns smartphones into lab-grade mobile medical diagnostics. In 2017, iXensor introduced the PixoTest® Blood Glucose Monitoring System as the world’s first US FDA-approved smartphone camera-based blood test. Based on the PixoTech® platform, iXensor has ventured into at-home self-testing and clinical point-of-care diagnostics across infectious diseases, women’s health, diabetes, and cardiovascular diseases.
Media Contact
Spokesperson: Patrick Liao
Website: www.ixensor.com
Email: pr@ixensor.com
Phone: +886-928-570-208